Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Daily News

Best Exercise for Heart Health? Some Hints of Intensity’s Role

Michael O'Riordan

December 02, 2021

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Daily News

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Michael O'Riordan

June 08, 2017

News Daily News

Alirocumab to Remain On Market While Companies Clash Over Patents

Michael O'Riordan

February 09, 2017

News Daily News

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

Michael O'Riordan

November 01, 2016

News Daily News

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

Michael O'Riordan

April 14, 2016

News Conference News

ASCOT: Unexplained Long-Term Mortality Benefit Found with Atorvastatin

August 29, 2011

News Daily News

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

May 27, 2011

Advertisement

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Best Exercise for Heart Health? Some Hints of Intensity’s Role

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Top News in Endovascular Therapy: 2018

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Alirocumab to Remain On Market While Companies Clash Over Patents

Pfizer Discontinues Investigational PCSK9 Inhibitor Bococizumab

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

ASCOT: Unexplained Long-Term Mortality Benefit Found with Atorvastatin

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content